BCR and acute lymphoblastic leukemia: Ph+ clinical protocols have the main focus on multiagent chemotherapy in combination with tyrosine kinase inhibitors; this combination significantly improved outcomes in adults with newly diagnosed BCR/ABL1-positive ALL [27].